AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00108316
Drug: Fluoxetine (Liquid Prozac)
RxNorm normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02172378
Drug: Placebo inhalation capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04066803
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
Trial: NCT00470743
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00470743
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004898
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02046382
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
Trial: NCT02392156
Drug: non-Fc FVIII replacement products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
Trial: NCT02392156
Drug: non-Fc FIX replacement products
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
Trial: NCT02046382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
Trial: NCT01493557
Drug: Pradaxa, within 30 minutes after a meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
Trial: NCT01356225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN placebo
Trial: NCT00404079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
Trial: NCT00385658
Drug: Fluvastatin extended release, fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00385658
Drug: Fixed combination simvastatin/ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00624546
Drug: Prevacid Solutabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID Prevacid Solutabs
Trial: NCT02702674
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch tablet containing no active drug material given before induction of labor
Trial: NCT04270968
Drug: topical none steroidal anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
Trial: NCT04236362
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT01890148
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral BD administration of 45 mg AZD5069
Trial: NCT03979859
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03355066
Drug: SM08502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM08502 tablets to be administered orally.
Trial: NCT00682565
Drug: CK-1827452 24mg and 6 mg iv infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
Trial: NCT00682565
Drug: CK-1827452 12.5mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5mg oral immediate release capsule
Trial: NCT00682565
Drug: CK-1827452 48 mg and 11 mg iv infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
Trial: NCT00682565
Drug: Placebo iv infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo iv infusion
Trial: NCT00682565
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral immediate release capsule
Trial: NCT00514761
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral vial
Trial: NCT00514761
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT04202952
Drug: HEC110114 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily
Trial: NCT00913328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo once daily
Trial: NCT01219855
Drug: Cohort 1 CTAP101 Capsules- 60µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60µg of CTAP101 capsules given once daily for 42 days.
Trial: NCT01219855
Drug: Cohort 1 CTAP101 Capsules - 90µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90µg of CTAP101 capsules given once daily for 42 days.
Trial: NCT02593942
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1-0.5 mcg/kg/min infusion
Trial: NCT02251067
Drug: Placebo to match VPI-2690B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00643669
Drug: AL-3789 Sterile Suspension
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration by anterior juxtascleral depot
Trial: NCT00610714
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral once daily dose
Trial: NCT02115763
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02115763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00398034
Drug: Testosterone Gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04163458
Drug: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in pre-filled pen, subcutaneous administration
Trial: NCT04163458
Drug: MENOPUR powder and solvent for solution for injection, 75 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in vials (powder and diluent), subcutaneous administration
Trial: NCT01248585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets taken once daily for 5 days
Trial: NCT04315597
Drug: Laif® 900, BAY98-7108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x daily, 1 tablet, 900 mg
Trial: NCT04315597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x daily, 1 tablet, 900 mg
Trial: NCT03213834
Drug: DNase
RxNorm normalized name: DNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
Trial: NCT01756404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
Trial: NCT02956317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT00029926
Drug: 2-deoxy-2 [F-18] fluoro-2-d-glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02050958
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00371566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04686383
Drug: CAL056 mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: 20 mg CAL056 mesylate/tablet
Trial: NCT02233023
Drug: Bromocriptine and other dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01835899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to BI 1015550
Trial: NCT00858637
Drug: Placebo of Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Trial: NCT00858637
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Trial: NCT00858637
Drug: Placebo of MCI-196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Trial: NCT00604695
Drug: Sterile Saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of IV sterile saline
Trial: NCT00318370
Drug: Chemo Plus Far
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
Trial: NCT02448914
Drug: TRIGEL
RxNorm normalized name: Trigels F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive TRIGEL. Treatment order is determined by randomization.
Trial: NCT02918539
Drug: florbetapir F 18 PET scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
Trial: NCT00608842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle placebo administered via intralipomal injection.
Trial: NCT00308971
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
Trial: NCT00308971
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for alpha lipoic acid; 2 pills daily for 4 months
Trial: NCT00253929
Drug: Intra-arterial infusion of adenosine
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00253929
Drug: intra-arterial infusion of caffeine
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00253929
Drug: intra-arterial infusion of acetylcholine
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01512108
Drug: oral anti-diabetic drug
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
Trial: NCT03205176
Drug: AZD5153
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
Trial: NCT01548066
Drug: Control placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
Trial: NCT00977587
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day
Trial: NCT01290744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 12 months
Trial: NCT01740557
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01188304
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeated daily doses
Trial: NCT02982057
Drug: O.M.T
RxNorm normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00559221
Drug: FLAG+IDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine, cytarabine, G-CSF
Trial: NCT02573740
Drug: ABT-957
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00869570
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
Trial: NCT03380026
Drug: Valchlor 0.016 % Topical Gel
RxNorm normalized name: Valchlor 0.016 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply valchlor nightly on select lesions.
Trial: NCT02855645
Drug: Trichosanthes root
RxNorm normalized name: Trichosanthes kirilowii root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
Trial: NCT02855645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
Trial: NCT04028141
Drug: Procedural sedation with ketofol in a 1 on 4 ratio
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years.
Trial: NCT03209466
Drug: Placebo Comparator with physiological saline sterile solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
Trial: NCT03468920
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
Trial: NCT03468920
Drug: PO Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen PO 1000mg once pre-operatively
Trial: NCT03468920
Drug: PO Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO placebo capsule compounded to match PO Acetaminophen capsule
Trial: NCT03468920
Drug: IV Solution Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will serve as the placebo for the IV Acetaminophen intervention
Trial: NCT02776059
Drug: Standard of care + pegfiltrastim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
Trial: NCT02776059
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone or pentoxifyline for 28 days only
Trial: NCT01100359
Drug: liposome-encapsulated doxorubicin citrate
RxNorm normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01166425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
Trial: NCT03030950
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to give normal saline to the other group as a placebo
Trial: NCT03873324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsules
Trial: NCT02542813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
Trial: NCT00386243
Drug: Co-Analgesic Therapy
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram
Trial: NCT00386243
Drug: Opioid Analgesics
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
Trial: NCT02781610
Drug: Standard of care IV antibiotic(s)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
Trial: NCT00291486
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
Trial: NCT04083651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
Trial: NCT00281918
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT04345523
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for the treatment of COVID-19 in hospitalized patients
Trial: NCT03658733
Drug: esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
Trial: NCT03658733
Drug: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
Trial: NCT06037135
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
Trial: NCT01511016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
Trial: NCT04627207
Drug: CKD-330 1 Tab. and D085 1 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other names: Reference